$AMRN News

Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM)

Amarin to Report Third Quarter 2026 Financial Results and Host Conference Call on October 28, 2026

Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026

New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients

Amarin to Present New REDUCE-IT and EPA Analyses at ESC Congress 2026

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026

JP Morgan Reinstates Underweight on Amarin Corp, Announces $13 Price Target

Amarin (AMRN) Q2 2026 Earnings Call Transcript

Amarin Corp PLC (AMRN) Q2 2026 Earnings Call Highlights: Strategic Growth Amidst Revenue Challenges

Amarin Corporation plc (AMRN) Q2 2026 Earnings Call Transcript

Amarin Reports Second-Quarter Results as Partnered International Strategy Gains Momentum

Amarin Q2 Earnings Call Highlights

Amarin Posts Surprise Q2 Profit on Cost Discipline, Shares Rise Pre-Market (NASDAQ:AMRN)

Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence

Amarin Corp Q2 Sales $42.211M Miss $44.550M Estimate

Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026

Amarin: The Market Is Pricing A 55% Chance Of A Sale That Isn't Coming

Amarin Highlights Recent FDA Approval Of Injectable Apolipoprotein C-III Therapies For Treatment Of Severe Hypertriglyceridemia, Defined As Triglycerides Greater Than Or Equal To 500 mg/dL

Is Amarin (AMRN) Outperforming Other Medical Stocks This Year?

Generic drugmakers gain key victory in ‘skinny label’ patent case